AZD 6610

CAS No. 810677-36-2

AZD 6610( AZD6610 )

Catalog No. M16027 CAS No. 810677-36-2

AZD 6610 is a dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist for treatment of diabetes mellitus.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 963 Get Quote
50MG 1962 Get Quote
100MG 2520 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    AZD 6610
  • Note
    Research use only, not for human use.
  • Brief Description
    AZD 6610 is a dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist for treatment of diabetes mellitus.
  • Description
    AZD 6610 is a dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist for treatment of diabetes mellitus.Diabetes Phase 2 Discontinued.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    AZD6610
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    PPAR
  • Recptor
    PPAR
  • Research Area
    Metabolic Disease
  • Indication
    Diabetes

Chemical Information

  • CAS Number
    810677-36-2
  • Formula Weight
    455.595
  • Molecular Formula
    C27H37NO5
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(O)C(OCC)CC1=CC=C(OCC(N(CCCCCC)CCC2=CC=CC=C2)=O)C=C1
  • Chemical Name
    2-ethoxy-3-(4-(2-(hexyl(phenethyl)amino)-2-oxoethoxy)phenyl)propanoic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Darnell M, et al. J Pharmacol Exp Ther. 2012 Oct;343(1):134-44. 2. Ericsson A, et al. Physiol Rep. 2017 Mar;5(5). pii: e13186.
molnova catalog
related products
  • β-Glycerol phosphate...

    β-Glycerol phosphate disodium salt pentahydrate is a protein phosphatase inhibitor.

  • LY518674

    LY518674 decreases triglycerides and increases HDL-C and is used for the treatment of atherosclerosis.

  • Dauricine

    Dauricine has pulmonary toxicity, can produce pulmonary injury in CD-1 mice by the metabolism of Dauricine mediated by CYP3A.